Results 61 to 70 of about 5,546 (214)

Acromegaly: pathogenesis & treatment [PDF]

, 2019
Acromegaly is a multi-system disorder whose etiology is most often traced back to a growth hormone-secreting pituitary adenoma (PA). Growth hormone (GH) secretion promotes insulin-like growth factor 1 (IGF-1) release from peripheral tissues, leading to ...
Tilvawala, Megha
core  

The treatment of hyperinsulinemic hypoglycaemia in adults: an update [PDF]

, 2016
Treatment of hyperinsulinemic hypoglycaemia (HH) is challenging due to the rarity of this condition and the difficulty of differential diagnosis.
A. Colao, A. Faggiano, A. Pia, G. Pizza, M. V. Davi′, null null, V. Guarnotta   +6 more
core   +1 more source

Re‐Evaluation of Fixed Dosing Versus Body Size‐Based Dosing Approaches for Large Molecule Therapeutics in Adults

Clinical Pharmacology &Therapeutics, Volume 118, Issue 5, Page 1015-1021, November 2025.
Wang et al.1 (2009) and Zhang et al.2 (2011) recommended a fixed dosing approach for large molecule therapeutics for first‐in‐human (FIH) trials, based on the finding that the majority of α values (body size effect on clearance) were < 0.5 across 12 monoclonal antibodies (mAbs) and 18 therapeutic proteins (TPs) and peptides, and fixed dosing provides ...
Andrew B. SyBing, Huili Chen, Diane D. Wang   +2 more
wiley   +1 more source

Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly

Journal of the Formosan Medical Association, 2016
The aim of the present study was to evaluate the serial changes of GH and IGF-1 in seven patients with naïve, active acromegaly following presurgical treatment of the somatostatin analog pasireotide long-acting release (LAR) and octreotide LAR.
Jan-Shun Chang, Ham-Min Tseng, Tien-Chun Chang   +2 more
doaj   +1 more source

Managing Cushing's disease: the state of the art. [PDF]

, 2014
Cushing's disease is a rare chronic disease caused by a pituitary adenoma, which leads to excess secretion of adrenocorticotropic hormone (ACTH). The over-production of ACTH leads to hyperstimulation of the adrenal glands and a chronic excess of cortisol,
Boscaro M, Casanueva FF, COLAO, ANNAMARIA, FERONE, DIEGO   +3 more
core   +1 more source

Tumor‐infiltrating immune cells predict the response to somatostatin receptor ligands only in somatotropinomas naïve to medical therapy

Journal of Neuroendocrinology, Volume 37, Issue 11, November 2025.
Abstract Tumor‐infiltrating immune cells (TICs) are important components of the tumor microenvironment (TME). They regulate somatotroph adenoma treatment responses to therapy with somatostatin receptor ligands (SRLs), mediated by soluble factors and cytokines. In this study, we assessed the effect of SRLs treatment on TICs.
Sabrina Chiloiro, Alessandra Vicari, Antonella Giampietro, Pier Paolo Mattogno, Natalia Cappoli, Greis Konini, Rosalinda Calandrelli, Liverana Lauretti, Simona Gaudino, Mario Rigante, Guido Rindi, Alessandro Olivi, Laura De Marinis, Antonio Bianchi, Francesco Doglietto, Marco Gessi, Alfredo Pontecorvi   +16 more
wiley   +1 more source

Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course

Diagnostics, 2021
Somatostatin analogues are considered to be the first line of treatment in acromegaly. Somatostatin analogues of the first generation mainly target the somatostatin receptor (SSTR) subtype 2 and have been proven efficient in the majority of patients with
Robert Pichler, Ognian Kalev, Berndt Tomancok, Michael Sonnberger, Daniela Ehrlich, Marina Hodolic   +5 more
doaj   +1 more source

Peptide‐Based Biomaterials as a Promising Tool for Cancer Radiotherapy

Advanced Science, Volume 12, Issue 31, August 21, 2025.
This review provides a systematic overview of peptide‐based biomaterials in tumor radiotherapy, covering their roles as both radiosensitizers and radiopharmaceuticals. Peptide‐based radiosensitizers are generally divided into three categories: peptides as direct radiosensitizers, peptides as carriers of radiosensitizers, and targeted‐peptide‐modified ...
Qian Wang, Xinhui Chu, Jianfeng Liu
wiley   +1 more source

A 12-month phase 3 study of pasireotide in cushing's disease [PDF]

, 2012
BACKGROUND: Cushing's disease is associated with high morbidity and mortality. Pasireotide, a potential therapy, has a unique, broad somatostatin-receptor-binding profile, with high binding affinity for somatostatin-receptor subtype 5.
Biller BM, Colao A, Findling JW, Gu F, Maldonado M, Mills D, Newell-Price J, Petersenn S, Salgado LR, Schoenherr U   +9 more
core   +1 more source

Bilateral Adrenal Ablation for the Treatment of Ectopic ACTH Syndrome With Severe Hypokalemia: A Case Report and a Literature Review

Clinical Case Reports, Volume 13, Issue 8, August 2025.
ABSTRACT Ectopic ACTH secretion‐related Cushing's syndrome may manifest as a rapid onset of hypercortisolism, elevated urinary free cortisol (UFC) and blood ACTH concentrations, and hypokalemia. However, for patients whose primary lesions are difficult to remove, bilateral adrenalectomy is the recommended treatment method according to guidelines. Here,
Fang Sun, Yuyu Sun, Hongbo He, Zhigang Zhao, Hexuan Zhang, Nan Jiang, Zhiming Zhu   +6 more
wiley   +1 more source